

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

**COALITION FOR AFFORDABLE
DRUGS VII, LLC,**
Petitioner,

v.

**THE TRUSTEES OF THE UNIVERSITY OF
PENNSYLVANIA,**
Patent Owner.

Case IPR2015-01836

Patent 7,832,268

**PATENT OWNER'S OBSERVATIONS ON CROSS-EXAMINATION OF
PETITIONER'S REPLY WITNESS**

Dr. Zusman's Reply Deposition Transcript (Ex. 2306)

1. In Ex. 2306, on page 44, lines 9-15, in response to the question “And it was generally known that for lomitapide, side effects increase with dose, correct?” Dr. Zusman testified that “That dose was one of the factors that was associated with side effects in the previously conducted trials.” This testimony is relevant to Petitioner’s assertion that a person of ordinary skill in the art (POSA) would have been motivated to dose lomitapide according to the increasing dose titration regimen in Pink Sheet, purportedly with a reasonable expectation of success. *See, e.g.*, Petitioner’s Reply (Paper 30) at pages 12-15. This testimony is relevant because it demonstrates that contrary to Petitioner’s assertion, a POSA would not have been motivated to use lomitapide—which was known to have dose-dependent side effects—in an increasing dose titration regimen.

2. In Ex. 2306, on page 50, line 22 – page 51, line 14, Dr. Zusman agreed that Exhibit 1015 (Chang) states that “similar AST and ALT elevations of a magnitude sufficient to halt the development of BMS-20138 [lomitapide] were also reported.” This testimony is relevant to Petitioner’s contention that a POSA purportedly would have understood that “BMS abandoned lomitapide for business reasons.” *See, e.g.*, Petitioner’s Reply (Paper 30) at pages 11 and 21. This testimony is relevant because it demonstrates that a POSA would have understood that BMS discontinued lomitapide due to liver toxicity, undercutting any purported

motivation to restart development of lomitapide.

3. In Ex. 2306, on page 51, line 15 – page 54, line 14, Dr. Zusman admits that Exhibit 2001, which includes the Technology Donation Agreement, is dated “May 19, 2006” (*see* Ex. 2306, page 52, lines 3-6) and “is not prior art.” (*See* Ex. 2306, page 53, line 6.) This testimony is relevant to Petitioner’s contention that based on the Technology Donation Agreement, a POSA would have known that “BMS abandoned lomitapide for business reasons,” and to Dr. Zusman’s contention that BMS discontinued the development of lomitapide “based on existing market conditions.” *See, e.g.*, Petitioner’s Reply (Paper 30) at pages 11, 21. This testimony is relevant because it demonstrates that a POSA would not have had access to the Technology Donation Agreement as of the claimed priority date, and thus this document could not have influenced a POSA’s decision on whether to restart lomitapide development following BMS’s discontinuation of the drug.

Dated: October 28, 2016

Respectfully submitted,
GOODWIN PROCTER LLP

/William G. James/

(Reg. No. 55,931)

GOODWIN PROCTER LLP

901 New York Avenue NW

Washington, DC 20001

Tel: 202-346-4046

Fax: 202-346-4444

wjames@goodwinprocter.com

Attorney for Patent Owner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing **PATENT OWNER'S OBSERVATIONS ON CROSS-EXAMINATION OF PETITIONER'S REPLY WITNESS** was served electronically via e-mail on October 28, 2016 on the following:

Dr. Gregory Gonsalves
2216 Beacon Lane
Falls Church, Virginia 22043
(571) 419-7252
gonsalves@gonsalveslawfirm.com

Christopher Casieri
McNeely, Hare & War LLP
12 Roszel Road, Suite C104
Princeton, NJ 08540
(609) 731-3668
chris@miplaw.com

Counsel for Petitioner Coalition
for Affordable Drugs VIII, LLC

Respectfully submitted,

Dated: October 28, 2016

/Russell W. Warnick/
Russell W. Warnick